| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/18/2009 | CN100469391C Use of human lysozyme in preparation of medicine for hemorrhoid |
| 03/18/2009 | CN100469390C Use of bromelain in preparing medicament for increasing individual IL-8 content |
| 03/18/2009 | CN100469389C Nano-grade polypeptide anti-dental caries material, producing method and tooth-paste containing said material |
| 03/18/2009 | CN100469361C Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress |
| 03/17/2009 | US7504499 Methods of attaching biological compounds to solid supports using triazine |
| 03/17/2009 | US7504484 Antibodies to the PRO1561 polypeptide |
| 03/17/2009 | US7504483 α-β C4BP-type recombinant heteromultimeric proteins |
| 03/17/2009 | US7504482 Recombinant soluble Fc receptors |
| 03/17/2009 | US7504481 TRP channel family member, LTRPC3 polypeptides |
| 03/17/2009 | US7504480 Nucleotide sequences coding polypeptides for use in the diagnosis, prevention and treatment cell proliferative and tumor disorders |
| 03/17/2009 | US7504479 Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses |
| 03/17/2009 | US7504383 metal at least partially enclosed by a discrete tubular, nanostructure composed of a plurality of aromatic homodipeptides |
| 03/17/2009 | US7504382 Protease inhibitors for coronaviruses and SARS-CoV and the use thereof |
| 03/17/2009 | US7504381 polymer of positively charged amino acid residues and at least one omega -amino-fatty acid residue; stable, non-toxic and avoiding development of resistance |
| 03/17/2009 | US7504380 Antimicrobial peptide isolated from halocynthia aurantium |
| 03/17/2009 | US7504379 combinations of platelet derived growth factor, vascular endothelial growth factor, and angiopoietin-2 |
| 03/17/2009 | US7504378 Viricides; induction immunology response; compounds according to invention specifically inhibit NS3 protease and do not show significant inhibitory activity against other serine proteases such as human leukocyte elastase, porcine pancreatic elastase, bovine pancreatic chymotrypsin, or cysteine proteases |
| 03/17/2009 | US7504376 administering a beta-alanylhistidine dipeptide and a glycine, an insulin, an insulin mimic, or an insulin-action modifier to increase blood plasma concentrations of beta-alanine and/or creatine; dietary supplements and sports drinks. |
| 03/17/2009 | US7504375 Antimicrobial polypeptides |
| 03/17/2009 | US7504374 Method for inducing deposition and maturation of bone comprising a co-therapeutic regimen of LMP-1 and BMP-2 |
| 03/17/2009 | US7504247 2-O sulfatase compositions and methods of degradation therewith |
| 03/17/2009 | US7504237 Polynucleotides encoding interferon gamma polypeptides |
| 03/17/2009 | US7504232 Identifying immunomodulators for diagnosis and treatment of inflammatory, granulomatous, fibrosis, multiple sclerosis, bacterial or viral diseases |
| 03/17/2009 | US7504231 Sustained release; synergistic mixture of inhibition of neurotransmitter synthesis and analgesics |
| 03/17/2009 | US7504228 Integrin linked kinase modulation of monocyte activation |
| 03/17/2009 | US7504224 Which comprises three N-helices and at least two, but not three, of the three C-helices of the trimer-of-hairpin structure of HIV gp41; inhibits infection of cells; drug screening; gene therapy |
| 03/17/2009 | US7504212 Cancer monitoring and therapeutics |
| 03/17/2009 | US7504211 Methods of using EPHA2 for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells |
| 03/17/2009 | US7504206 Postweaning multisystemic wasting syndrome and porcine circovirus from pigs |
| 03/17/2009 | US7504115 Shark cartilage extracts and use thereof for immunomodulation |
| 03/17/2009 | US7504111 Protein from gonococcus (Neisseria gonorrhoeae), including a specific amino acid sequence; antigens for vaccines, immunogenic compositions, and/or diagnostics; useful for distinguishing between gonococcus and meningococcus |
| 03/17/2009 | US7504110 Protein-based Streptococcus pneumoniae vaccines |
| 03/17/2009 | US7504108 Polypeptides; immunogenic compositions; generating immune responses; kits |
| 03/17/2009 | US7504105 Antibody for diagnosising immunology disorders |
| 03/17/2009 | US7504102 Therapeutic mixture comprising immunoglobulin specific to vitronectin receptor for use in diagnosis, prevention and treatment of restenosis |
| 03/17/2009 | US7504101 Methods for enhancing antigen-specific immune response using antibodies that bind OX-40 |
| 03/17/2009 | US7504100 Method for delivering a biological compound using neural progenitor cells derived from whole bone marrow |
| 03/17/2009 | US7504099 Regeneration of tendons by grafting genetic engineered stem cells comprises nucleic acid coding for BMP-2 and SMAD proteins or variants |
| 03/17/2009 | US7504097 Interferon-alpha polypeptides and conjugates |
| 03/17/2009 | US7504096 Methods for in vitro fertilization |
| 03/17/2009 | US7504092 Cosmetic or pharmaceutical composition comprising peptides, uses and treatment processes |
| 03/17/2009 | CA2374333C Dietary supplement energy-providing to skeletal muscles and protecting the cardiovascular tract |
| 03/17/2009 | CA2338638C Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity |
| 03/17/2009 | CA2330025C Methods and compositions useful for modulation of angiogenesis using tyrosine kinase src |
| 03/17/2009 | CA2319094C Antimicrobial peptides |
| 03/17/2009 | CA2309159C Skin penetration enhancing components |
| 03/17/2009 | CA2262546C Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation |
| 03/17/2009 | CA2258882C Compositions and methods for altering the biodistribution of biological agents |
| 03/17/2009 | CA2171434C Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| 03/12/2009 | WO2009033121A2 Molecules and methods for treatment and detection of diabetes |
| 03/12/2009 | WO2009033004A1 Protein cages and their uses |
| 03/12/2009 | WO2009032954A1 Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity |
| 03/12/2009 | WO2009032943A2 Methods and compositions for delivery of growth factor to fibrous connective tissue |
| 03/12/2009 | WO2009032845A2 Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
| 03/12/2009 | WO2009032749A2 Salicylanilide modified peptides for use as oral therapeutics |
| 03/12/2009 | WO2009032380A2 Branched carboxylic acids as fuel lubricity additives |
| 03/12/2009 | WO2009032352A1 Macrocyclic compounds and methods of treatment |
| 03/12/2009 | WO2009032351A1 Natural product agents, derivatives, and methods of treatment |
| 03/12/2009 | WO2009032349A1 Macrocyclic compounds, protease inhibition, and methods of treatment |
| 03/12/2009 | WO2009032338A1 Apratoxin therapeutic agents: mechanism and methods of treatment |
| 03/12/2009 | WO2009032247A1 Synthetic peptide and peptide conjugates and related tissue coupling methods via transglutaminase enzyme |
| 03/12/2009 | WO2009032172A2 Platinum compositions as treatment for oct-related cancers |
| 03/12/2009 | WO2009032171A1 Subcutaneous administration of alpha-galatosidase a |
| 03/12/2009 | WO2009032148A1 Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits |
| 03/12/2009 | WO2009031943A1 Method for monitoring diabetes insulin therapy |
| 03/12/2009 | WO2009031920A1 Hypoglycemic agent and method for the production thereof |
| 03/12/2009 | WO2009031918A1 Apolactoferrin compositions and methods of the use thereof for treating viral hepatitis c |
| 03/12/2009 | WO2009031916A1 Vip antagonists in the form of an agent for treating psoriasis |
| 03/12/2009 | WO2009031842A1 Use of trim72 as a target for muscle and heart enhancer |
| 03/12/2009 | WO2009031835A2 Cell permeable nm23 recombinant proteins, polynucleotides encoding the same, and anti-metastatic composition comprising the same |
| 03/12/2009 | WO2009031051A2 Stabilized anthocyanin compositions |
| 03/12/2009 | WO2009030932A1 Methods for reducing meiotic non-disjunction |
| 03/12/2009 | WO2009030931A1 Compound for controlling appetite |
| 03/12/2009 | WO2009030866A2 Method for purifying the factor viii and the von willebrand factor |
| 03/12/2009 | WO2009030774A1 Truncated glp-1 derivatives and their therapeutical use |
| 03/12/2009 | WO2009030771A1 Peptides derivatized with a-b-c-d- and their therapeutical use |
| 03/12/2009 | WO2009030738A1 Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| 03/12/2009 | WO2009030679A1 Method for prolonging longevity |
| 03/12/2009 | WO2009030499A1 Use of glp-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission |
| 03/12/2009 | WO2009030498A2 Use of gip for the treatment of disorders associated with dysfunctional synaptic transmission |
| 03/12/2009 | WO2009030094A1 Function and use of new lysosome-associated apoptosis-inducing protein containing ph and fyve domains (lapf) |
| 03/12/2009 | WO2009030093A1 Functions and uses of human protein phosphatase 1 inhibitor-2 |
| 03/12/2009 | WO2009030088A1 Function and use of a new human calcium/calmodulin-dependent protein kinase ii inhibitor |
| 03/12/2009 | WO2009030087A1 Functions and uses of phosphatidylethanolamine binding protein 4 |
| 03/12/2009 | WO2009030086A1 Functions and uses of human bone marrow stromal cell-derived growth inhibitor |
| 03/12/2009 | WO2009030066A1 Polyethylene glycol modified interferon alpha 2b and preparation method and applicatioins thereof |
| 03/12/2009 | WO2009030065A1 INTERFERON ALPHA 2a MODIFIED BY POLYETHYLENE GLYCOL, ITS SYNTHESIS PROCESS AND APPLICATION |
| 03/12/2009 | WO2009030040A1 Antimicrobial activity of bacteriocin-producing lactic acid bacteria |
| 03/12/2009 | WO2009029991A1 Agents with angiogenic and wound healing activity |
| 03/12/2009 | WO2009015314A3 Modified lecithin-cholesterol acyltransferase enzymes |
| 03/12/2009 | WO2009014564A9 Modified plasminogen activator inhibitor type-1 molecule and methods based thereon |
| 03/12/2009 | WO2009011988A3 Cyclodepsipeptides with antineoplastic activity and methods of using to inhibit cancer and microbial growth |
| 03/12/2009 | WO2009009587A3 Apoptosis-modulating protein therapy for proliferative disorders and nanoparticles containing the same |
| 03/12/2009 | WO2009008901A3 Peptide and small molecule agonises of epa and their uses in diseases |
| 03/12/2009 | WO2009007120A3 Tnf superfamily collectin fusion proteins |
| 03/12/2009 | WO2009005798A8 Antifungal formulation and method of preparation |
| 03/12/2009 | WO2009004058A3 Novel prolactin compounds |
| 03/12/2009 | WO2008157304A3 Stabilized thrombin compositions |
| 03/12/2009 | WO2008156829A3 Promoterless cassettes for expression of alphavirus structural proteins |
| 03/12/2009 | WO2008146167A3 Improved methods of using phosphoantigens together with interleukin-2 for the treatment of cancer |